By clicking below you acknowledge that you are navigating away from temaetfs.com and will be connected to temafunds. Tema Global Limited manages both domains. Please tack note of Tema's privacy policy, terms of use, and disclosures that may vary between sites.
Invest directly by choosing one of the brokers below
Get in Touch
HLTH
Tema Healthcare AI ETF
Invest in Healthcare’s Next Era
Why Invest in HLTH?
Healthcare Growth Outlook
U.S. healthcare spending is forecast to reach $9 trillion by 2034,1 creating vast opportunity for AI applications
¹CMS, Jul 2026
First-of-Its-Kind ETF
Offers the only pure-play ETF focused exclusively on AI healthcare disruptors
Investment Expertise
Actively managed by a Yale- and Penn-trained physician turned veteran healthcare investor
Portfolio Highlights
10x Genomics is a life sciences tools company whose single-cell and spatial genomics platforms generate the high-resolution biological data used to train foundational models of human disease.
Twist Bioscience (TWST) is a synthetic biology company whose silicon-based DNA synthesis platform supports AI-driven drug discovery, diagnostic development, and biotechnology research.
Intuitive Surgical is the pioneer and global leader in robotic-assisted surgery, whose da Vinci platform combines robotic instrumentation, advanced imaging, data analytics, and AI-enabled software to support surgeons and has been used in more than 20 million procedures worldwide.
Portfolio holdings are subject to change. Review current holdings below.
Fund Overview
Fund Details
As of October 26, 2026
Ticker
HLTH
CUSIP
87975E768
Inception Date
07/20/26
Total Expense Ratio
0.75%
AUM
$11,709,104
Shares Outstanding
420,000
Primary Exchange
NASDAQ
# of Holdings
33
Portfolio Manager
David K. Song, MD, PhD, CFA
Fund Summary
The Tema Healthcare AI ETF (HLTH) invests in companies leveraging AI to transform healthcare across drug discovery, diagnostics, clinical application, and patient care.
Portfolio Breakdown
Top 10 Holdings
As of October 26, 2026
Company
% of Nav
10X GENOMICS INC
6.81%
NATERA INC
5.58%
TWIST BIOSCIENCE CORP
5.37%
INTUITIVE SURGICAL INC
5.32%
ILLUMINA INC
5.15%
REVOLUTION MEDICINES INC
4.80%
CYTOKINETICS INC
4.76%
COGENT BIOSCIENCES INC
4.67%
THERMO FISHER SCIENTIFIC INC
4.62%
GUARDANT HEALTH INC
4.59%
Country Breakdown
United States
98.80%Cayman Islands
0.86%Cash & Cash Equivalents
0.37%Industry Breakdown
Health Care
97.65%Financials
2.01%Cash & Cash Equivalents
0.37%ETF Characteristics
As of October 26, 2026
Return on Equity
55.6%
Weighted Average Market Cap
$
9,215
M
Price-to-Earnings (P/E)
NA
Price-to-Book Value (P/BV)
NA
Price-to-Sales (P/S)
3.1x
- Performance
- Distributions
- Premium / Discount
Prices & Performance
{id=225622316144, createdAt=1793106067063, updatedAt=1793106067063, 9='{type=number, value=0.2229}', 2='{type=list, value=[{id=217129167670, name='Healthcare AI ETF'}]}', 10='{type=number, value=1790726400000}', 3='{type=string, value=NAV}', 11='{type=string, value=M}'}
As of
Sep 30, 2026
- Sep 30, 2026
- Sep 30, 2026
HLTH
3 months
1 Year
3 Years
5 Years
Since inception
NAV
22.29%
22.29%
Market Price
22.61%
22.61%
Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.
The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.
Distributions
Record Date
Ex-Date
Payable Date
Total Distribution
Income
0.15
-0.05
0.16
0.16
0.12
0.15
0.2
0.22
0.23
0.2
0.18
0.31
0.17
0.18
0.13
0.19
0.23
0.13
Premium/Discount
Сhart
Table
Days Traded at Nav
Days Traded at Premium
Days Traded at Discount
2026/Q3
1
51
0
HLTH NAV / Market Price
NAV$27.88
Daily Change
$0.20
0.71%
Market Price$27.92
Daily Change
$0.25
0.91%
Premium/Discount0.15%
30-Day Median Bid/Ask Spread0.40%
As of October 26, 2026
October-26
September-26
August-26
July-26
Portfolio Manager
David K. Song, MD, PhD, CFA
David Song is the Head of Healthcare and Investment Partner at Tema ETFs. David has led biotechnology and healthcare investment teams throughout his extensive 25-year career at Rockefeller Capital Management, Millennium and Balyasny. He studied Economics and Biochemistry at Yale, is a medical doctor and has a PhD in Applied Economics from Wharton. David is a CFA charter holder.
How to buy
.svg){kind=small}
*Neither Tema ETFs LLC nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.
Latest Research & Insights
Stay informed with our latest research, insights, and market analysis to make better investment decisions.
The AI Drug Discovery Revolution
Explore how AI is turning drug discovery into more of an engineering discipline capable of unlocking more treatments and value for patients and healthcare.
Why Healthcare Is Worth Revisiting as 2026 Draws to a Close
Explore why healthcare investments are becoming increasingly attractive as market ownership hits historic lows, despite strong growth and innovation prospects.
What to Expect When You’re Expecting… A Mid-Term Election
Learn what the 2026 midterms could mean for AI regulation, U.S. manufacturing, healthcare, and the investment opportunities that follow.
Subscribe for Updates
Risk Information
Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing.
Investing involves risk including possible loss of principal. There is no guarantee the fund's investment strategy will be successful.
Sector Focus Risk: The Fund may invest a significant portion of its assets in one or more sectors and thus will be more susceptible to the risks affecting those sectors than funds that have more diversified holdings across a number of sectors. The Fund anticipates that it may be subject to some or all of the risks described below.
Healthcare Sector Risk: To the extent the Fund focuses on the healthcare sector, the Fund may be more susceptible to the particular risks that may affect companies in the healthcare sector than if it were invested in a wider variety of companies in unrelated sectors. The profitability of companies in the healthcare sector may be adversely affected by the following factors, among others: extensive government regulations, restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, an increased emphasis on outpatient services, changes in the demand for medical products and services, a limited number of products, industry innovation, changes in technologies and other market developments. The expiration of a company’s patents may adversely affect that company’s profitability. Healthcare companies are subject to competitive forces that may make it difficult to raise prices and, in fact, may result in price discounting. Many new products in the healthcare sector may be subject to regulatory approvals. The process of obtaining such approvals may be long and costly, and such efforts ultimately may be unsuccessful. Companies in the healthcare sector may be thinly capitalized and may be susceptible to product obsolescence.
Information Technology Sector Risk: Information technology companies face intense competition, both domestically and internationally, which may have an adverse effect on their profit margins. Like other technology companies, information technology companies may have limited product lines, markets, financial resources or personnel. Companies in the information technology sector are heavily dependent on patent and intellectual property rights. The loss or impairment of any of these rights may adversely affect the profitability of these companies or the Fund’s performance.
Tema ETFs LLC serves as the investment adviser to Tema Healthcare AI ETF (the “Fund”), and Tidal Investments LLC serves as a sub-adviser to the Fund. The Fund is distributed by Vigilant Distributors, LLC, which is not affiliated with Tema ETFs LLC nor Tidal Investments LLC. Check the background of Vigilant Distributors, LLC on FINRA’s BrokerCheck.